Mendus KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023
About The Event
Join us for a virtual KOL Event with Mendus, featuring Dr. Arjan van de Loosdrecht, Professor of Hematology at Amsterdam UMC, who will discuss the current treatment landscape for patients with Acute Myeloid Leukemia (AML) and the development of Mendus’ lead product candidate vididencel as a potential AML maintenance therapy.
The event will focus on the new survival data being presented at the American Society of Hematology (ASH) Annual Meeting, taking place December 9-12, 2023. The results will include relapse-free and overall survival data from the ongoing ADVANCE II monotherapy Phase 2 trial and immunomonitoring data.
A live question and answer session will follow the formal presentations.